A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis

• Status: Unknown status
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This Phase 3, open-label, triple arm study aims to evaluate the overall survival (OS) of fotemustine versus the combination of ipilimumab and fotemustine or the combination of Ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Italian Network for Tumor Biotherapy Foundation
• Collaborator: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Fotemustine; Ipilimumab; Nivolumab

Criteria

Inclusion Criteria:

• Willing and able to give written informed consent.

• Histologic diagnosis of malignant melanoma;

• Stage IV melanoma;

• No prior therapy for advanced (unresectable Stage III or Stage IV) disease;

• No previous systemic corticosteroid therapy within 7 days;

• Prior adjuvant treatment with IFN or other immunotherapy allowed with exception of anti-CTLA-4;

• Presence of asymptomatic brain metastases: patients must have measurable metastases in the brain, defined as lesions that can be accurately measured in 2 dimensions as ≥ 0.5 cm (maximum 2 cm) in the brain MRI with contrast;

• Pts who have been previously treated with brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT) and/or surgery, must have developed new measurable brain lesions;

• Life expectancy ≥ 12 weeks;

• ECOG performance status of 0 or 1 (see Appendix 2);

• Normal laboratory tests were required.

• Subjects must have known BRAF V600E mutation status or consent to BRAF V600E mutation testing per local institutional standard.

• Negative screening tests for HIV, Hepatitis B, and Hepatitis C.

• Men and women, of and over 18 years old.Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug

Exclusion Criteria:

• Any malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix;

• Primary ocular or mucosal melanoma.

Medical History and Concurrent Diseases:

• Symptomatic brain metastases requiring immediate local intervention (radiotherapy (RT) and/or surgery);

• Autoimmune disease

• Any underlying medical condition, which in the opinion of the investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events, such as a condition associated with frequent diarrhea.

Prohibited Treatments and/or Therapies:

• Concomitant therapy with any anti-cancer agent; immunosuppressive agents; any non-oncology vaccine therapy used for prevention of infectious diseases (for up to 1 month prior to or after any dose of study drug); surgery or radiotherapy ; other investigational anti-cancer therapies; or chronic use of systemic corticosteroids

• Previous treatment with other investigational products, including cancer immunotherapy, within 30 days;

• Prior treatment with anti-CTLA-4 and/or , anti-PD1/PD-L1 or fotemustine.

Sex and Reproductive Status:

• WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the study;

• Women who are pregnant or breastfeeding;

• Women with a positive pregnancy test on enrollment or prior to investigational product administration;

• Sexually active fertile men not using effective birth control if their partners are WOCBP.

Other Exclusion Criteria:

• Prisoners or subjects who are involuntarily incarcerated;

• Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.